H. Lundbeck A/S

Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

As the pharmaceutical industry invests more money than ever before to develop new weight loss treatments, a growing number of patient advocates and academics say companies have, ironically, failed to

H. Lundbeck is squarely focused on central nervous system disorders, arguably one of the most challenging areas of drug development, but the small specialty pharma is showing that investments in the t